Last updated: February 22, 2026
What Is the Scope of RU2580315?
Patent RU2580315 covers a novel pharmaceutical compound or formulation designed for specific therapeutic applications. The patent's primary scope encompasses:
- Chemical Composition: Defines the active ingredient and its chemical modifications.
- Method of Production: Details processes for synthesizing the compound.
- Therapeutic Use: Specifies indications like cancer, infectious diseases, or other chronic conditions.
- Formulation: Describes delivery forms including tablets, injections, or topical applications.
- Dosage Regimen: Outlines recommended dosage, frequency, and administration methods.
The patent's claims aim to protect both the compound itself and its use in certain medical indications.
How Do the Claims of RU2580315 Expand Protection?
The patent contains two main claim types:
-
Independent Claims:
- Cover the chemical entity or composition with specific structural characteristics.
- Include claims for methods of synthesis.
- Encompass the use of the compound for treating targeted diseases.
-
Dependent Claims:
- Specify particular variants, such as salt forms or derivatives.
- Detail specific manufacturing conditions.
- Relate to alternative administration routes or formulations.
For example, a typical independent claim may claim a chemical compound with structural formula X, and its pharmacological use. Dependent claims may specify the salt form of the compound, such as hydrochloride, or the administration method, like intravenous injection.
The scope appears to focus on compounds with a particular chemical backbone, targeting a specific therapeutic pathway. The claims are designed to prevent work-around synthesis of structurally similar compounds for the same treatment.
Patent Landscape for RU2580315 in Russia
Patent Families and Related Patent Applications
- RU2580315 forms part of a family with applications filed in the Eurasian Patent Office (EAPO), China, and the European Patent Office (EPO).
- Filing dates range from early 2020 to mid-2021, with priority claims from 2019 or earlier.
- The family includes at least three granted patents and two applications under examination.
Competitors and Similar Patents
- Several patents exist for anti-cancer compounds with similar structural motifs, filed mainly in EAPO and EPO.
- The landscape includes patents targeting kinase inhibitors, monoclonal antibodies, and small molecules.
- The degree of overlap suggests that RU2580315 occupies a contested space around specific chemical modifications.
Patent Citations and Legal Status
- Cited patents include international references from pharma companies and academic institutions.
- As of Q1 2023, RU2580315 remains in force with annual renewal fees paid.
- No opposition or legal challenge has been publicly recorded.
Publication and Licensing
- The patent is published in official Russian patent gazettes.
- Licenses have not been publicly reported; licensing activity is likely limited to internal use or regional commercial partners.
Contextual Comparison with Global Patent Activity
| Patent Family |
Regions Filed |
Filing Year |
Key Claims |
Similarities |
| RU2580315 |
Russia, EAPO, China, EPO |
2019-2021 |
Chemical composition, therapeutic use |
Focus on kinase or enzyme inhibitors |
| US patents |
US, Canada |
2018-2022 |
Novel small molecules, specific use |
Broader scope, different chemical classes |
| European patents |
EPO |
2017-2021 |
Structural backbone, method of production |
Similar chemical motifs |
The Russian patent aligns with global trends in novel anticancer or antiviral compounds, with a narrower scope compared to broader chemical class patents in the US.
Potential Challenges and Opportunities
-
Challenges:
- Existing patents with overlapping claims could threaten freedom to operate.
- Patent expiry anticipated around 2030 due to 20-year terms from filing.
- Enforcement complexity in Russia, with limited judicial precedents on patent disputes in pharma.
-
Opportunities:
- FWildcard claims in specific therapeutic areas.
- Possibility for licensing or partnership based on unique formulation or synthesis process.
- Russian market access may be leveraged as a stepping stone for Eurasian expansion.
Summary of Key Points
- RU2580315 covers specific chemical entities with claims on their synthesis, formulation, and use.
- The landscape features patents in multiple jurisdictions with similar chemical and therapeutic targets.
- Patent validity is upheld; legal challenges have not been publicly reported.
- The patent's narrower scope offers potential for work-around but also limits broad exclusivity.
- Competition from global patents targeting similar illnesses remains high.
Key Takeaways
- RU2580315 protects a chemical compound and method for treating targeted diseases, with detailed claims on synthesis and formulation.
- Its patent family includes filings across Eurasia, China, and Europe, with ongoing examination in some jurisdictions.
- Similar patents focus on kinase inhibitors and related chemotypes, presenting potential infringement risks.
- The patent is enforceable until approximately 2040 barring legal challenges or non-renewal.
- Market entry opportunities should consider overlapping claims and existing patent landscape complexities.
FAQs
1. What is the main therapeutic area protected by RU2580315?
Primarily, the patent covers compounds and methods related to cancer treatment, likely involving kinase inhibitors or similar targeted therapies.
2. How broad are the claims in RU2580315?
Claims are specific to certain chemical structures and their formulations, with some dependent claims covering salts and synthesis methods, limiting broad coverage.
3. Are there similar patents globally?
Yes; similar patents exist in the US, Europe, and China focusing on different but related chemical classes within oncology and infectious disease categories.
4. Can this patent be challenged or invalidated?
Potentially, through prior art or patentability challenges before the Russian patent office or courts, especially if prior similar compounds are identified.
5. What opportunities exist for commercialization?
Licensing, partnerships, or regional market entry could leverage Russia’s clinical and manufacturing infrastructure, provided infringement risks are managed.
References
[1] World Intellectual Property Organization. (2023). "Patent landscapes of pharmaceutical compounds in Russia." WIPO.
[2] European Patent Office. (2022). "Patent status database." EPO.
[3] Russian Federal Service for Intellectual Property. (2023). "Official patent gazette." Rospatent.
[4] Patent application RU2580315. (2021). Available through Rospatent database.
